Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience. (Q48387202)
Jump to navigation
Jump to search
scientific article published in July 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience. |
scientific article published in July 2012 |
Statements
Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience (English)
S Crvenkova
Lj Ivkovski
A Dimovski